|
|
|
|
|
|
by lotsofpulp
1315 days ago
|
|
|
Or the dirt cheap insulin does not work as well as the newer patented insulin that a private company paid to do R&D for. There is nothing stopping Congress from passing a bill to fund insulin R&D that provides the newest insulin technology without being patented, but the fact that they do not and would rather sit in their pulpit and “grill” private company representatives proves that it is all a show. We (sufficient voters) want to pay for nothing, but expect everything. |
|
|
The fact is, Lilly isn't even the largest profiteer. The insane margins of insulin are actually split between Lilly, PBMs (like optumRX and CareMark) and insurance companies, through an incredibly complex system of rebates and vouchers. Turning over that rock reveals more writhing maggots than anyone cares to see.